Invest in the Future with Venture Capital
Institutional investing with top-tier¹ fund managers and some of today’s most innovative startups and growth companies.
Peakline Venture Capital provides access to top-tier funds and co-investments that are typically out of reach for most investors. After diligently vetting thousands of opportunities, we’ve curated a portfolio of leading funds and venture-backed companies. This allows our investors to invest alongside larger insitutions at lower minimums—without the need for a dedicated venture capital team.
JOIN OUR LIST TO STAY UP-TO-DATE ON OUR MARKET VIEWS AND ACTIVITIES
Our Competitive Edge
Institutional Scale
Experienced Team
Distinctive Visibility
Seeded and Transparent Portfolio
Data Advantage
Why Manager Selection is Critical
Large institutions tend to allocate significantly more to Venture Capital due in part to their enhanced access and desire for long-term, compounding returns.¹ Our team’s deep
relationships and dedicated resources provide us the ability to partner with these top tier managers¹, enabling our investors access to an institutional quality portfolio.
Historical Returns
Top quartile Venture capital has generated ~25% returns for over a decade, outperforming top quartile of every other asset class over a long-term horizon.¹
+
+
Strong Historical Persistence
Venture capital manager returns have historically persisted, following top quartile funds with another top quartile fund 45% of the time.¹
=
Manager Selection is Critical
You should only invest in venture capital if you can access the top firms.
We're Proud of Our Long-Term Partnerships
“Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren.”
JOHN SOANDSO
Executive Managing Director, Andreessen Horowitz
“Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren.”
JOHN SOANDSO
Executive Managing Director, Andreessen Horowitz
“Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren.”
JOHN SOANDSO
Executive Managing Director, Andreessen Horowitz
CO-INVESTMENT SPOTLIGHT
Enveda Biosciences
In 2024, Peakline Partners was able to participate in an oversubscribed $130 million Series C funding round led by Kinnevik and FPV into Enveda, a biotechnology company using AI to translate nature into new medicines.
The new funding will enable Enveda to deliver clinical catalysts in 2025 and 2026 across multiple programs with strong commercial opportunities, continue advancing their deep pipeline of 10 Development Candidates and multiple discovery programs, and invest in their world-leading platform. This news comes on the heels of the company’s first clinical trial and announcement of a foundation model for metabolomics trained on the world’s largest collection of experimental mass spectra.
Featured companies in our fund manager's portfolios
Co-Investment
Co-Investment
